In this article, we will be taking a look at the 12 best psychedelic stocks to buy in 2025.
The Therapeutic Potential and Investment Boom in Psychedelic Medicine
In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of “alternate reality.” One class of hallucinogenic substances that can produce unusual states of consciousness is psychedelics. LSD and chemicals originating from plants are among the many chemical substances included in this class. Psychedelics have the power to change or heighten feelings, thoughts, and energy levels, which frequently leads to spiritual experiences. They are divided into two primary categories: serotonergic chemicals (like LSD) and empathogens and dissociative drugs (like PCP). These medications are being investigated for therapeutic uses in addition to recreational ones, and they have shown promise in the treatment of several illnesses, including opiate addiction, severe depressive disorders, treatment-resistant depression, panic disorder, and post-traumatic stress disorder.
The revival of interest in psychedelics has been greatly aided by venture capital investors. Startups in this sector saw a spike in investor interest around the beginning of 2020, which was dubbed the “psychedelic renaissance.” On February 16, 2023, Clara Burtenshaw, a partner at Neo Kuma Ventures, the biggest European venture capital fund specializing in psychedelic investments, shared her excitement about psychedelic healthcare, saying:
“Psychedelic healthcare is a very exciting area because it’s this apex of drugs, clinics, and experimental treatments.”
Growth and Promise of the Psychedelic Drugs Market
Many psychedelic-focused pharmaceutical businesses are working to have their medications approved by the government. Psilocybin and other hallucinogens are showing great promise in treating disorders including schizophrenia and depression. The US psychedelic drugs market is projected to grow from $4.51 billion in 2025 to $15.62 billion by 2032, with a CAGR of 16.8%. This growth is part of a larger global trend, with the worldwide market expected to reach $11.93 billion by 2029, growing at a CAGR of 16.9%.
Psilocybin (magic mushrooms) is the most widely used psychedelic drug in the United States, with an estimated 8 million American adults using it in 2023, according to a survey conducted by RAND Corporation. Around 12% of respondents reported lifetime use, and 3.1% used it in the past year. LSD use has also risen significantly, particularly among individuals aged 18-25, with usage increasing from 0.9% in 2002 to 4% in 2019. The LSD market is projected to grow from $145.9 million in 2024 to $265.7 million by 2034. MDMA, although not providing specific usage data, remains popular, especially in research for PTSD treatment. Ketamine has gained attention for its depression treatment potential, particularly with the FDA approval of Spravato nasal spray.
Market growth is driven by rising mental health issues, increasing demand for alternative treatments, and regulatory changes as several US cities and states decriminalize or legalize psychedelics. Psychedelic drugs are showing therapeutic potential in treating conditions like depression, anxiety, PTSD, and addiction. Ongoing research and development are also expanding their therapeutic applications.
Photo by Florian van Duyn on Unsplash
Our Methodology
We selected the following psychedelic stocks based on the hedge fund sentiment, as assessed from Insider Monkey’s database, which tracks over 1,000 elite hedge funds as of the end of Q4 2024. The stocks are listed in ascending order according to the number of hedge fund holders for each stock.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the 12 best psychedelic stocks to buy in 2025.
12. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
Number of Hedge Fund Holders: 3
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. Its main product, NRX-101, combines D-cycloserine and lurasidone, two FDA-approved drugs. The company stands out for its innovative use of NMDA receptor modulators and atypical antipsychotics to treat mental health disorders.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is making significant strides in developing treatments for mental health disorders, particularly suicidal treatment-resistant bipolar depression and chronic pain. Its lead product, NRX-101, has been designated as a Breakthrough Therapy by the FDA, showing potential for large-scale market impact. As one of the best psychedelic stocks, the company is also advancing toward New Drug Applications (NDAs) for NRX-101 and NRX-100 (IV ketamine), with key approval decisions expected by 2025. The company estimates that NRX-101 could generate hundreds of millions in annual revenue, targeting around 3 million cases in the U.S.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is also expanding strategically through its subsidiary, Hope Therapeutics, which is setting up interventional psychiatry clinics, aiming for $100 million in revenue by the end of 2025. Financially, the company has made impressive progress. In Q3 2024, it reduced its net operating losses by 74% and cut research and development expenses significantly. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ended the quarter with $1.6 million in cash and secured an additional $5.4 million in financing.
11. Cybin Inc. (NYSE:CYBN)
Number of Hedge Fund Holders: 9
Cybin Inc. (NYSE:CYBN) is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapies for mental health disorders. It creates novel compounds from traditional psychedelics like psilocybin and DMT to treat conditions such as major depressive disorder, anxiety, and addiction. The company’s business model centers on drug discovery, development, and the potential commercialization of these treatments.
Cybin Inc. (NYSE:CYBN) is advancing its psychedelic drug pipeline with several promising clinical programs. Its lead programs, CYB003 and CYB004, aim to improve the effectiveness and scalability of traditional psychedelics. CYB003, a deuterated psilocin analog, is being tested in a Phase 3 trial for major depressive disorder (MDD), with early Phase 2 results showing high response and remission rates. CYB004, a deuterated DMT formulation, is being developed for generalized anxiety disorder, with Phase 2 results expected in 2025. The company is also exploring non-hallucinogenic treatments through its CYB005 program.
In terms of financials, Cybin Inc. (NYSE:CYBN) ended Q3 2025 with C$136.3 million in cash, providing the company with the flexibility to continue its clinical programs and growth strategies. Despite a net loss of C$10.5 million for the quarter, the company has improved its operational efficiency compared to last year. Its new at-the-market equity program could also provide additional funding for its initiatives.
With promising clinical data, including CYB003’s Breakthrough Therapy Designation from the FDA, Cybin Inc. (NYSE:CYBN) is well-positioned for future growth. The company’s strong intellectual property portfolio and experienced management team add to its potential in the rapidly growing psychedelic medicine market.
10. GH Research PLC (NASDAQ:GHRS)
Number of Hedge Fund Holders: 10
GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders using mebufotenin (5-MeO-DMT), a potent psychedelic compound. Its lead product, GH001, is an inhalable form of 5-MeO-DMT aimed at treating treatment-resistant depression (TRD).
GH Research PLC (NASDAQ:GHRS), standing tenth among the best psychedelic stocks to buy in 2025, announced positive results from its Phase 2b clinical trial of GH001 for treatment-resistant depression (TRD). The trial showed a significant reduction in depression symptoms, with a -15.2 point improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to +0.3 points in the placebo group. This rapid antidepressant effect was seen just two hours after treatment. The trial also showed a strong safety profile, with no serious adverse events, and most patients were discharged within an hour of treatment. These results led to a 79.07% increase in GH Research’s stock price.
In its Q3 2024 financial report, GH Research PLC (NASDAQ:GHRS) reported strong financial health, with $193.8 million in cash and assets as of September 30, 2024. However, research and development expenses rose to $8.4 million, and general and administrative expenses increased to $4.2 million, reflecting the company’s expansion efforts. The net loss for the quarter was $12.1 million, up from $5.6 million the previous year.